Core Insights - Profitability has become a central focus in the market, shifting from narratives driven by multiple expansions and AI optimism to companies that consistently generate earnings regardless of macroeconomic conditions [2][3] - Institutional investors are emphasizing quality and expected future profitability, with firms like Fidelity and Invesco highlighting the importance of consistent earnings and margins [3] - The article presents a list of the 10 most profitable S&P 500 stocks to consider for investment, based on specific financial metrics [4][6] Methodology - The selection process involved screening S&P 500 stocks with a Return on Equity (ROE) of at least 15% and a net profit margin of at least 20% [6] - The final selection was limited to companies that have reported significant developments likely to influence investor sentiment and are favored by analysts and hedge funds [6][7] Company Highlights - **Amgen Inc. (NASDAQ:AMGN)**: - Wells Fargo raised the price target to $390, citing potential market expansion for therapies that could reach $15 billion in U.S. sales by 2036 [8] - Jefferies initiated coverage with a Hold rating and a $350 price target, noting a 35% stock gain over six months due to strong commercial execution [9] - Amgen reported Q4 adjusted EPS of $5.29, exceeding estimates, with revenue of $9.9 billion, indicating strong performance and growth momentum [10] - **Broadcom Inc. (NASDAQ:AVGO)**: - Announced the first end-to-end Post-Quantum Cryptography-safe in-flight network encryption solution, with over 120,000 units deployed [11] - Introduced a 3nm 400G/lane optical PAM-4 DSP, enhancing bandwidth density for AI-driven data centers [12] - Morgan Stanley raised its price target to $470, citing AI-driven upside and improved long-term visibility [13]

Company Overview - Elanco Animal Health Incorporated (NYSE:ELAN) specializes in veterinary medicine, providing products for the protection and treatment of pets and farm animals, including parasiticides, vaccines, therapeutics, and medicated feed additives [3]. Stock Performance - The stock has shown a remarkable performance, increasing by 137% over the past 12 months and nearly 17% since the beginning of 2026 [1]. - Following a strong quarterly report, Elanco's stock rose by 6.6% [1]. Financial Highlights - The company reported a 12% revenue growth, attributed to strong performance in both pet health and farm animal segments [1]. - Elanco achieved a 2-cent earnings beat, reporting earnings of 11 cents per share [1]. - Management provided a solid full-year forecast, indicating confidence in continued growth [1][2]. Management and Strategy - The management has successfully turned the company around, demonstrating effective strategies that have impressed analysts [2].

Company Overview - Moderna, Inc. is a leading player in the biotech industry, recognized for its innovative mRNA technology and focus on developing vaccines and therapeutics, positioning it as a leader in the biomedical and genetics sector [1] Stock Performance - On February 16, 2026, UBS maintained a Neutral rating for Moderna, advising investors to hold the stock, with the stock priced at $42.23 and a revised price target adjusted from $34 to $36, indicating a cautious yet optimistic outlook [2] - Moderna's shares experienced a 5.3% increase on February 13, driven by investor interest in large-cap biotech companies, highlighting the positive sentiment surrounding the stock [3][6] - The stock has fluctuated between $41.23 and $44.80 on the day, with a 52-week high of $55.20 and a low of $22.28, reflecting its volatility in the market [5] Market Capitalization and Trading Volume - Moderna's market capitalization is approximately $16.5 billion, with a trading volume of 16,336,584 shares, indicating significant investor activity [4][6] Industry Sentiment - The biotech sector's improved outlook and institutional buying have contributed to positive sentiment surrounding Moderna, as investors are attracted to the company's blend of innovation and stability, recognizing its potential for sustained momentum beyond the pandemic-driven surge [4]

Group 1 - Elanco Animal Health Incorporated (NYSE:ELAN) has successfully turned around its operations, leading to a significant stock price increase of over 83% since January 21 [1] - The company specializes in products for the protection and treatment of pets and farm animals, including parasiticides, vaccines, therapeutics, and medicated feed additives [1] - Despite the positive turnaround, there are opinions suggesting that other stocks, such as Chewy, may present better investment opportunities within the same sector [1] Group 2 - There is a belief that certain AI stocks may offer greater upside potential and carry less downside risk compared to ELAN [2]